Skip to main content Skip to main menu
UF Health University of Florida
Division of Cardiovascular Medicine Department of Medicine, College of Medicine
Request a Patient Appointment: (352) 265-0820
Juan Vilaro

Juan Vilaro, MD

Associate Professor, Cardiovascular Medicine; Medical Director of Heart Transplant

Department: MD-CARDIOLOGY
Business Phone: (352) 265-0751
Business Email: juan.vilaro@medicine.ufl.edu

On This Page

About Juan Vilaro

My name is Dr. Juan Vilaro, and I am an associate professor of medicine in the division of cardiovascular medicine at the University of Florida. I received my medical degree from the University of Puerto Rico School of Medicine, completing a visiting clerkship in cardiovascular diseases at Mayo Clinic during the same tenure. I completed my residency in internal medicine at the University of Florida, serving as chief resident for the program. I then completed my training at UF, completing cardiology and advance heart failure/transplant cardiology fellowships. I’m board-certified in internal medicine and cardiovascular medicine, and my primary clinical interests are the evaluation and management of patients with advanced heart failure syndromes, including optimal patient selection for advanced therapies such as heart transplantation and different forms of mechanical circulatory support. In addition, I am also interested in devising new strategies for reducing hospital admissions in patients with chronic heart failure.

Accomplishments

  1. Exemplary Teacher Award

    College of Medicine

Teaching Profile

Courses Taught

  1. MDC6001 – Intro Clin Practice

    College of Medicine

  2. BMS6633 – The Cv System

    College of Medicine

Board Certifications

  • Cardiovascular Disease
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine

Clinical Profile

Specialties

  • Advanced Heart Failure and Transplant Cardiology
  • Cardiology

Areas of Interest

  • Echocardiogram
  • Heart Disease
  • Heart Failure
  • Heart Transplant
  • Hypertrophic Cardiomyopathy
  • Mechanical Circulatory Assist Device
  • Valvular Disease

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0001-5294-5397

Publications

Academic Articles

Grants

  1. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure

    Role:
    Principal Investigator
    Funding:
    BRIGHAM AND WOMENS HOSPITAL via ASTRAZENECA

  2. The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization

    Role:
    Principal Investigator
    Funding:
    INOVA HEALTH CARE SERVICES via NATL INST OF HLTH NHLBI

  3. A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of inhospital initiation of LCZ696 compared to valsartan in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization

    Role:
    Principal Investigator
    Funding:
    NOVARTIS PHARMACEUTICALS CORP

  4. VICTORIA Heart Failure (HF) Registry Characterizing the flow of patients hospitalized for heart failure decompensation during the prescreening phase of the VICTORIA (VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Study

    Role:
    Principal Investigator
    Funding:
    DUKE UNIVERSITY via MERCK SHARP & DOHME

  5. TRANSFORM-HF (ToRsemide compArisoN with furoSemide FOR Management of Heart Failure) Study

    Role:
    Principal Investigator
    Funding:
    YALE UNIV via NATL INST OF HLTH NHLBI

  6. PROVIDE-HF: Patient Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (Sacubitril/Valsartan) in Heart Failure

    Role:
    Principal Investigator
    Funding:
    DUKE UNIVERSITY via NOVARTIS PHARMACEUTICALS CORP

  7. 214 Fund – Vilaro Payroll Operating Account

    Active

    Role:
    Principal Investigator
    Funding:
    UNIV OF FLORIDA

  8. A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of inhospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF)

    Role:
    Principal Investigator
    Funding:
    NOVARTIS PHARMACEUTICALS CORP

  9. A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

    Role:
    Principal Investigator
    Funding:
    MERCK SHARP & DOHME

  10. INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

    Role:
    Co-Investigator
    Funding:
    BRIGHAM AND WOMENS HOSPITAL via NATL INST OF HLTH NHLBI

Education

  1. Fellowship – Cardiology – Heart Failure and Transplantation

    University of Florida

  2. Fellowship – Cardiology

    University of Florida

  3. Residency – Internal Medicine

    University of Florida

  4. Internship – Internal Medicine

    University of Florida

  5. Medical Degree

    University Puerto Rico

Contact Details

Phones:
Business:
(352) 265-0751
Emails:
Business:
juan.vilaro@medicine.ufl.edu
Addresses:
Business Mailing:
PO Box 100288
1329 SW 16TH ST
 GAINESVILLE FL 32608
Business Street:
PO Box 100288
 GAINESVILLE FL 32610